Elekta stock rises as CEO buys SEK 9.9 million in shares

Published on 09/15/2026 at 16:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elekta stock gained on September 15, 2026 after CEO Jacob Just-Bomholt bought 200,000 shares for SEK 9.9 million on Nasdaq Stockholm. The move comes as analysts’ average target of SEK 59.69 implies roughly 19 percent upside from the latest close.

Moderner Bestrahlungsraum mit High-Tech-Linearbeschleuniger in blauem Klinik-Ambiente — Fotorealistischer Bestrahlungsraum zeigt Elekta AB SE0000163628 mit modernem Linearbeschleuniger in klinischer High-Tech-Umgebung, Illustration mit AI erstellt.

Elekta AB (publ) stock (ISIN SE0000163628) traded higher on September 15, 2026 after Chief Executive Officer Jacob Just-Bomholt disclosed the purchase of 200,000 class B shares for a total of SEK 9.9 million, reinforcing management’s confidence in the Swedish radiation therapy specialist.

CEO share purchase supports Elekta stock

According to Zonebourse on September 15, 2026, Jacob Just-Bomholt bought 200,000 Elekta class B shares on Nasdaq Stockholm on September 11, 2026 at an average price of SEK 49.49 per share, corresponding to a total consideration of SEK 9.9 million.

The same report notes that, as of August 27, 2026, Just-Bomholt already held around 1.0 million Elekta shares, so the latest transaction increases his stake by about 20 percent on a share-count basis.Zonebourse

Analyst consensus and valuation backdrop

Zonebourse’s analyst overview, updated around September 15, 2026, shows Elekta covered by 14 analysts with an average recommendation of Hold and an average target price of SEK 59.69 per share, compared with a last closing price of SEK 50.05, implying a potential upside of about 19.3 percent if the consensus target is reached.Zonebourse

The same consensus snapshot indicates that Elekta’s shares closed at SEK 50.05 most recently and carry an ESG rating of BBB by MSCI, positioning the company in the mid-range of its medical equipment peer group on environmental, social and governance criteria.Zonebourse

Risk backdrop: short sellers and negative watch

Zonebourse’s news feed highlights that Millennium Capital Partners recently appeared as a new public short seller in Elekta and then dropped off the list of declared short positions again by September 15, 2026, underscoring that bearish interest has been active in the name but also volatile.Zonebourse

In addition, the same aggregation of recent articles points out that UBS reiterated a Sell recommendation on Elekta on September 8, 2026, arguing that risks around the company’s turnaround remain, while a note on September 9, 2026 reported that JP Morgan placed Elekta on negative watch alongside other Nordic medtech names.Zonebourse

Profitability trends and EV/EBIT comparison

An analysis of Elekta’s valuation on Eulerpool shows that the company’s EV/EBIT ratio stands at 10.32 for 2026, compared with 8.78 for 2025, representing an increase of 17.47 percent in the multiple year on year.Eulerpool

The same data suggest that Elekta’s enterprise value has risen faster than its EBIT between 2025 and 2026, which can reflect improved investor confidence or higher growth expectations, but it also means that the shares are valued more richly in relation to operating earnings than in the previous year.Eulerpool

Stock price level and trading details

Per the real-time Cboe Europe quote snapshot on Zonebourse at 13:20:13 on September 15, 2026, Elekta B shares traded at around SEK 51.45 on Nasdaq Stockholm, up 2.8% over the last five trading days, with a year-to-date change of plus 4.52% and a decline of 8.28% when measured over a longer 52-week horizon.Zonebourse

While detailed intraday volume and the precise 52-week high and low levels are not broken out in the same snapshot, the combination of a mid-range EV/EBIT ratio for 2026 and a price still below the average target of SEK 59.69 gives investors a sense of where Elekta stock currently stands between cautious sell ratings and supportive insider buying.Zonebourse